| Autor: |
Freeman BD; Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, United States of America., Martins YC; Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, United States of America., Akide-Ndunge OB; Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, United States of America., Bruno FP; Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, United States of America., Wang H; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, United States of America., Tanowitz HB; Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, United States of America.; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States of America., Spray DC; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States of America.; Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, United States of America., Desruisseaux MS; Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, United States of America.; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States of America. |
| Abstrakt: |
Plasmodium falciparum infection causes a wide spectrum of diseases, including cerebral malaria, a potentially life-threatening encephalopathy. Vasculopathy is thought to contribute to cerebral malaria pathogenesis. The vasoactive compound endothelin-1, a key participant in many inflammatory processes, likely mediates vascular and cognitive dysfunctions in cerebral malaria. We previously demonstrated that C57BL6 mice infected with P. berghei ANKA, our fatal experimental cerebral malaria model, sustained memory loss. Herein, we demonstrate that an endothelin type A receptor (ETA) antagonist prevented experimental cerebral malaria-induced neurocognitive impairments and improved survival. ETA antagonism prevented blood-brain barrier disruption and cerebral vasoconstriction during experimental cerebral malaria, and reduced brain endothelial activation, diminishing brain microvascular congestion. Furthermore, exogenous endothelin-1 administration to P. berghei NK65-infected mice, a model generally regarded as a non-cerebral malaria negative control for P. berghei ANKA infection, led to experimental cerebral malaria-like memory deficits. Our data indicate that endothelin-1 is critical in the development of cerebrovascular and cognitive impairments with experimental cerebral malaria. This vasoactive peptide may thus serve as a potential target for adjunctive therapy in the management of cerebral malaria. |
